These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7646996)

  • 21. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.
    Sundarapandiyan K; Keler T; Behnke D; Engert A; Barth S; Matthey B; Deo YM; Graziano RF
    J Immunol Methods; 2001 Feb; 248(1-2):113-23. PubMed ID: 11223073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
    Hansen HP; Matthey B; Barth S; Kisseleva T; Mokros T; Davies SJ; Beckett RP; Foelster-Holst R; Lange HH; Engert A; Lemke H
    Int J Cancer; 2002 Mar; 98(2):210-5. PubMed ID: 11857410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
    Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
    MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
    Scott CF; Goldmacher VS; Lambert JM; Chari RV; Bolender S; Gauthier MN; Blättler WA
    Cancer Immunol Immunother; 1987; 25(1):31-40. PubMed ID: 3496157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
    Ferrini S; Sforzini S; Canevari S
    Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
    [No Abstract]   [Full Text] [Related]  

  • 27. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
    Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
    Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
    Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
    Rosenblum MG; Cheung L; Kim SK; Mujoo K; Donato NJ; Murray JL
    Cancer Immunol Immunother; 1996 Feb; 42(2):115-21. PubMed ID: 8620520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
    J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
    Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
    Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
    Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
    Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
    Battelli MG; Buonamici L; Bolognesi A; Stirpe F
    Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
    Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
    Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different sensitivity of CD30+ cell lines to Ber-H2/saporin-S6 immunotoxin.
    Battelli MG; Bolognesi A; Olivieri F; Polito L; Stirpe F
    J Drug Target; 1998; 5(3):181-91. PubMed ID: 9606008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
    Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
    Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
    J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
    Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
    Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F
    Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.